CD274 Knockout HCT116 Cell Line

The choice depends on whether you are studying PD-L1 in a colorectal cancer context for MSI-H/dMMR cancer immunotherapy research. The Knockout line is the standard tool for asking whether PD-L1 is required for these processes in colorectal cancer context — HCT 116 is MSI-H (microsatellite instability-high), making this background highly relevant for PD-1/PD-L1 immunotherapy research since MSI-H/dMMR cancers are particularly responsive to anti-PD-1/PD-L1 therapy. Overexpression is useful for studying PD-L1 gain-of-function in colorectal context. For MSI-H colorectal cancer immunotherapy research, the EDITGENE CD274 Knockout in HCT 116 is uniquely valuable — pembrolizumab and nivolumab are FDA-approved for MSI-H/dMMR colorectal cancer (regardless of tissue of origin, FDA's first tissue-agnostic immunotherapy approval). This product complements the parallel CD274 Knockouts in HEK293 (biochemistry) and HeLa (imaging) for cross-background validation. Rescue with wild-type PD-L1 is the standard specificity control. The knockout is uniquely valuable for studying MSI-H/dMMR cancer immune evasion mechanisms and pembrolizumab/dostarlimab activity in colorectal cancer.

Primary applications: • MSI-H/dMMR cancer immunotherapy: HCT 116 is MSI-H, making this KO highly relevant for tissue-agnostic anti-PD-1 immunotherapy mechanism studies. • Colorectal cancer PD-L1 biology: in CRC context, characterization of PD-L1 immune evasion mechanisms. • Pembrolizumab/dostarlimab specificity: critical genetic control for tissue-agnostic MSI-H/dMMR-targeted immunotherapy. • MMR pathway interaction: parallel analysis with MLH1, MSH6, MSH3 KOs (all available in EDITGENE catalog) for MMR-PD-L1 immune evasion axis studies. EDITGENE recommends this HCT 116-based model for MSI-H colorectal cancer immunotherapy research and tissue-agnostic anti-PD-1 mechanism studies.

Yes. PD-L1 rescue in HCT 116 is well-suited for MSI-H cancer immunotherapy research: • Construct design: same considerations as PD-L1/HEK293 rescue. • Surface localization validation: confirm plasma membrane PD-L1 by cell surface staining. • MSI-H-context PD-L1 biology: rescue with WT PD-L1 enables systematic immune evasion mechanism studies in MSI-H CRC context. • Tissue-agnostic immunotherapy: pembrolizumab/dostarlimab specificity testing in MSI-H background. • Functional readout: rescue should restore PD-L1-dependent T cell suppression in CRC immunotherapy co-cultures. HCT 116 transduces efficiently with lentivirus and supports stable rescue line generation.